13F Holdings
中文EN

BCAX Bicara Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2023658 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-81.3%
TTM EPS YoY-164.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-54.2%
ROA-49.8%
ROIC (approx.)-67.1%
Asset turnover—

Leverage & solvency

Liabilities / assets11.1%
Debt / equity0.00x
Current ratio8.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense————$33.00M$24.80M$34.30M$19.90M
SG&A expense$19.23M$14.18M$12.74M$8.13M$7.70M$7.22M$7.46M$6.75M
Operating income-$75.71M-$59.95M-$60.24M-$41.12M-$40.68M-$32.02M-$41.79M-$26.64M
Pretax income-$71.19M-$55.38M-$56.16M-$37.33M-$36.29M-$27.34M-$36.77M-$20.77M
Income tax$54,000$61,000$52,000$53,000$40,000$52,000$72,000$179,000
Net income-$71.25M-$55.44M-$56.21M-$37.39M-$36.33M-$27.39M-$36.85M-$20.96M
EBITDA-$75.65M-$59.91M-$60.20M-$41.08M-$40.65M-$32.00M-$41.77M-$26.62M
EPS (basic)-1.04-0.82-0.93—-0.67-0.50-0.68—
EPS (diluted)-1.04-0.82-0.93—-0.67-0.50-0.68—
Weighted avg. shares (diluted)68.38M67.93M60.72M—54.56M54.54M54.46M—
Balance sheet
Cash & equivalents$82.02M$96.60M$323.46M$96.69M$171.67M$436.61M$462.06M$489.71M
Short-term investments$360.32M$400.66M$216.29M$318.12M$118.49M——$0
Current assets$451.41M$503.82M$544.91M$422.05M$297.37M$444.39M$470.75M$502.53M
PP&E, net$965,000$362,000$346,000$330,000$135,000$117,000$136,000$155,000
Total assets$460.64M$512.24M$553.60M$430.99M$424.69M$453.59M$478.08M$510.00M
Current liabilities$51.23M$43.48M$39.34M$28.95M$21.03M$17.23M$19.12M$17.99M
Total liabilities$51.23M$43.48M$39.64M$29.54M$21.91M$18.39M$19.12M$18.12M
Shareholders' equity$409.41M$468.77M$513.96M$401.45M$402.78M$435.20M$458.96M$491.88M
Shares outstanding66.35M65.93M65.55M56.60M54.61M54.56M54.53M54.44M
Cash flow statement
Operating cash flow-$56.13M-$44.21M-$37.51M-$23.89M-$29.25M-$25.59M-$28.11M-$30.03M
Capital expenditure$663,000$60,000$60,000$238,000$42,000$0$0$40,000
Free cash flow-$56.79M-$44.27M-$37.57M-$24.12M-$29.29M-$25.59M-$28.11M-$30.07M
Investing cash flow$38.34M-$184.99M$100.94M-$82.33M-$236.12M$0$0-$40,000
Financing cash flow$3.21M$2.33M$163.34M$31.23M$436,000$135,000$460,000-$975,000
Depreciation & amortization$60,000$44,000$44,000$43,000$24,000$19,000$19,000$15,000
Stock-based compensation$9.98M$8.24M$5.86M$4.45M$3.61M$3.49M$3.45M$3.18M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.